Terms: = Kidney tumors AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Prognosis
47 results:
1. Exosomal long non-coding RNA MALAT1: a candidate of liquid biopsy in monitoring of Wilms' tumor.
Sharma D; Singh A; Wilson C; Swaroop P; Kumar S; Yadav DK; Jain V; Agarwala S; Husain M; Sharawat SK
Pediatr Surg Int; 2024 Feb; 40(1):57. PubMed ID: 38353772
[TBL] [Abstract] [Full Text] [Related]
2. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma.
Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B
J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262
[TBL] [Abstract] [Full Text] [Related]
3. Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma.
Rashedi S; Mardani M; Rafati A; Khavandi MM; Mohammadi F; Javanshir S; Sarallah R; Dolatshahi M; Sabahi M; Azadnajafabad S; Tavolinejad H; Rezaei N
J Clin Lab Anal; 2022 Oct; 36(10):e24670. PubMed ID: 35989533
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort.
Toide M; Saito K; Yasuda Y; Tanaka H; Fukuda S; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2022 Aug; 20(4):e276-e282. PubMed ID: 35410826
[TBL] [Abstract] [Full Text] [Related]
5. Interactive Data Visualization Tool for Patient-Centered Decision Making in kidney Cancer.
Shee K; Pal SK; Wells JC; Ruiz-Morales JM; Russell K; Dudani S; Choueiri TK; Heng DY; Gore JL; Odisho AY
JCO Clin Cancer Inform; 2021 Aug; 5():912-920. PubMed ID: 34464153
[TBL] [Abstract] [Full Text] [Related]
6. Circulating RNA in kidney Cancer: What We Know and What We Still Suppose.
Cinque A; Vago R; Trevisani F
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071652
[TBL] [Abstract] [Full Text] [Related]
7. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 May; 22(5):690-701. PubMed ID: 33798493
[TBL] [Abstract] [Full Text] [Related]
8. [Pulmonary lymphangioleiomyomatosis (LAM)].
Theegarten D; Hager T
Pathologe; 2021 Feb; 42(1):35-39. PubMed ID: 33420570
[TBL] [Abstract] [Full Text] [Related]
9. Morbidity, perioperative outcomes and complications of robot-assisted radical prostatectomy in kidney transplant patients: A French multicentre study.
Felber M; Drouin SJ; Grande P; Vaessen C; Parra J; Barrou B; Matillon X; Crouzet S; Leclerc Q; Rigaud J; Prudhomme T; Doumerc N; Bergerat S; Lang H; Laine C; Robert G; Gobert A; Granger B; Rouprêt M
Urol Oncol; 2020 Jun; 38(6):599.e15-599.e21. PubMed ID: 31948931
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Significance of Cyclin D1 Expression in Renal Cell Carcinoma: a Systematic Review and Meta-analysis.
Li Z; Liu J; Zhang X; Fang L; Zhang C; Zhang Z; Yan L; Tang Y; Fan Y
Pathol Oncol Res; 2020 Jul; 26(3):1401-1409. PubMed ID: 31748879
[TBL] [Abstract] [Full Text] [Related]
11. PET imaging in renal cancer.
Lindenberg L; Mena E; Choyke PL; Bouchelouche K
Curr Opin Oncol; 2019 May; 31(3):216-221. PubMed ID: 30747736
[TBL] [Abstract] [Full Text] [Related]
12. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract] [Full Text] [Related]
13. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract] [Full Text] [Related]
14. PTEN in kidney cancer: A review and meta-analysis.
Que WC; Qiu HQ; Cheng Y; Liu MB; Wu CY
Clin Chim Acta; 2018 May; 480():92-98. PubMed ID: 29408173
[TBL] [Abstract] [Full Text] [Related]
15. Identification and validation of a 44-gene expression signature for the classification of renal cell carcinomas.
Wang Q; Gan H; Chen C; Sun Y; Chen J; Xu M; Weng W; Cao L; Xu Q; Wang J
J Exp Clin Cancer Res; 2017 Dec; 36(1):176. PubMed ID: 29208006
[TBL] [Abstract] [Full Text] [Related]
16. A new plasma biomarker enhance the clinical prediction of postoperative acute kidney injury in patients with hepatocellular carcinoma.
Zhou X; Wang L; Wang G; Cheng X; Hu S; Ke W; Li M; Zhang Y; Song Z; Zheng Q
Clin Chim Acta; 2017 Dec; 475():128-136. PubMed ID: 29031454
[TBL] [Abstract] [Full Text] [Related]
17. Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan.
Takayanagi S; Mukasa A; Nakatomi H; Kanno H; Kuratsu JI; Nishikawa R; Mishima K; Natsume A; Wakabayashi T; Houkin K; Terasaka S; Yao M; Shinohara N; Shuin T; Saito N
Neurol Med Chir (Tokyo); 2017 Feb; 57(2):59-65. PubMed ID: 28070114
[TBL] [Abstract] [Full Text] [Related]
18. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Zhang HL; Sheng XN; Li XS; Wang HK; Chi ZH; He ZS; Ye DW; Guo J
BMC Cancer; 2017 Jan; 17(1):16. PubMed ID: 28056874
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma.
Shen L; Zhou L; Liu X; Yang X
Diagn Interv Radiol; 2017; 23(2):100-105. PubMed ID: 28050950
[TBL] [Abstract] [Full Text] [Related]
20. Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma.
Gang G; Hongkai Y; Xu Z
J Cancer Res Ther; 2015; 11(4):1026. PubMed ID: 26881596
[TBL] [Abstract] [Full Text] [Related]
[Next]
